Skip to main content
. 2022 Dec 26;11(1):4. doi: 10.3390/medsci11010004

Table 1.

Outcomes studied in the trials of use of anakinra in heart failure.

Treatment Ejection Fraction Effects Effects
Anakinra CPX parameters and HF events Peak aerobic capacity (VO2) and ventilatory efficiency (VE/VCO2 slope).
Adverse events Clinical, cardiac, and non-cardiac deaths, hospitalization, and injection-site reactions.
QoL measures General improvement in quality of life
Biomarkers High-sensitive C-reactive protein and NT-proBNP levels